Pharmacoeconomics: theory and practice
№1, 2018, Vol.6
Saratov State Medical University named afer V.I. Razumovsky, Saratov, Russia
First Moscow State Medical University I.M. Sechenov (Sechenov University), Moscow, Russia
Moscow State Medical University I.M. Sechenov (Sechenov University), Moscow, Russia
Moscow State Medical University I.M. Sechenov (Sechenov University), Moscow, Russia
Ryazan State Medical University, Ryazan, Russia
Ryazan State Medical University, Ryazan, Russia
Saratov State Medical University named afer V.I. Razumovsky, Saratov, Russia
Pyatigorsk Medical Pharmaceutical Institute of Volgograd Medical State University, Pyatigorsk, Russia
Pyatigorsk Medical Pharmaceutical Institute of Volgograd Medical State University, Pyatigorsk, Russia
Pacifc State Medical University, Vladivostok, Russia
Saratov State Medical University named afer V.I. Razumovsky, Saratov, Russia
Saratov State Medical University named afer V.I. Razumovsky, Saratov, Russia
Clinical Trials and Healthcare Technology Assessment Centre of Moscow Department of Healthcare, Moscow, Russia
Clinical Trials and Healthcare Technology Assessment Centre of Moscow Department of Healthcare, Moscow, Russia
1 Kuban State Medical University, Krasnodar, Russia 2 Kuban State Agrarian University named afer I.T. Trubilin, Krasnodar, Russia
Saratov State Medical University named afer V.I. Razumovsky, Saratov, Russia
Saratov State Medical University named afer V.I. Razumovsky, Saratov, Russia
Saratov State Medical University named afer V.I. Razumovsky, Saratov, Russia
Abstract: We provided a pharmacoeconomic evaluation of the treatment of gastric cancer in the second line of therapy with ramucirumab, using the relative value analysis method. Ramucirumab is the only anti-angiogenic drug registered for the treatment of advanced gastric cancer. In comparison with the standard regimens of the second line of chemotherapy for gastric cancer, the use of the ramucirumab has a statistically significant advantage, increasing the median overall survival by 30%. Ramucirumab (Cyramza) cost of treating per one patient is 1 761 564 RUB. From the perspective of relative value analysis the cost of an additional unit of effectiveness of ramucirumab is comparable or even lower than the same criteria of other antitumor drugs of monoclonal antibodies already included in the national EDL. Consequently, ramucirumab can be characterized as an acceptable technology. The budget impact analysis showed that providing patients with advanced gastric cancer with the ramucirumab is characterized by a lower burden on the drug support budget for oncological patients than bevacizumab, trastuzumab and cetuximab in the therapy of the oncology nosologies, at the their approval date. According to the results of the budget impact analysis on the drug supply of ramucirumab, 200 patients will additionally require 329.19 million rubles, which is only 0.64% of the budget for the treatment of cancer in 2016. Key words: gastric cancer, pharmacoeconomics, cost-effectiveness analysis, budget impact analysis, relative value analysis, bevacizumab, cetuximab, ramucirumab, trastuzumab.
Bronchial asthma (BA) is an urgent public health problem. Treatment of asthma is based on the level of disease control. The change in the structure of basic therapy and the replacement of inhalers are the main causes of exacerbations of asthma and an increase in material costs. «Symbicort Maintenance And Reliever Therapy» (SMART) promote effective control of asthma: providing monitoring and decrease future risk of exacerbation. Improving control of asthma will reduce the steroid load, to reduce the number of hospitalizations and the number of ambulance calls. Key words: bronchial asthma, preferential provision of medicines, combined basic therapy, efficiency
